Relmada Therapeutics (RLMD) Other Operating Expenses (2012 - 2022)
Relmada Therapeutics (RLMD) reported Other Operating Expenses of $6.4 million for Q2 2022, up 878407.05% on a QoQ basis from $723.0 in Q1 2013.
Relmada Therapeutics (RLMD) has 3 years of Other Operating Expenses data on file, last reported at $6.4 million in Q2 2022.
- Quarterly Other Operating Expenses changed N/A year-over-year to $6.4 million in Q2 2022, while the trailing twelve-month figure through Mar 2023 was $6.4 million (changed N/A YoY) and the FY2022 annual result came in at $6.4 million, changed N/A from the prior year.
- Other Operating Expenses grew to $6.4 million in Q2 2022 per RLMD's latest filing, from $723.0 in the prior quarter.
- Across five years, Other Operating Expenses topped out at $6.4 million in Q2 2022 and bottomed at $6.4 million in Q2 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 6.35 Mn |
| Feb 28, 2013 | 723.00 |
| Nov 30, 2012 | 309.00 |
| Aug 31, 2012 | 1,048.00 |